Last reviewed · How we verify
Engerix™
At a glance
| Generic name | Engerix™ |
|---|---|
| Also known as | GSK Biologicals' vaccine 103860 |
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Hepatitis B Challenge Dose in Adults (V232-059-10) (PHASE3)
- A Bridging Study: Comparing Two Lots of Sci-B-Vac™ and Engerix-B in Healthy Adults (PHASE3)
- Lot-to-lot Consistency of Sci-B-Vac™ in Adults (PHASE3)
- Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants (PHASE2)
- A Study to Evaluate Persistence of Hepatitis B Antibodies, Immunogenicity and Safety of Engerix™-B Kinder Challenge Dose, in Adolescents Vaccinated With Four Doses of Infanrix™ Hexa During Infancy (PHASE4)
- Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299) (PHASE3)
- Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc (PHASE4)
- Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |